In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonists c7E3 fab on the activated clotting time - Response

被引：0
|
作者：
Amar, T
Coller, BS
机构：
来源：
CIRCULATION | 1997年 / 96卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3794 / 3794
页数：1
相关论文
共 50 条
  • [21] Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA)
    Zahn, R
    Haubelt, H
    Bechtloff, S
    Schneider, S
    Frilling, B
    Rustige, J
    Marsalek, P
    Seidl, K
    Senges, J
    Hellstern, P
    HERZ, 2003, 28 (05) : 445 - 452
  • [22] PLATELET GLYCOPROTEIN IIB/IIIA MONOCLONAL-ANTIBODY (C7E3) REDUCES DISTAL EMBOLIZATION DURING PERCUTANEOUS INTERVENTION OF SAPHENOUS-VEIN GRAFTS
    CHALLAPALLI, RM
    EISENBERG, MJ
    SIGMON, K
    LEMBERGER, J
    CIRCULATION, 1995, 92 (08) : 2908 - 2908
  • [23] Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha(IIb)beta(3) (GPIIb/IIIa) antagonists, c7E3 and DMP728
    Tsao, PW
    Forsythe, MS
    Mousa, SA
    THROMBOSIS RESEARCH, 1997, 88 (02) : 137 - 146
  • [24] Assessment of plasma fibrinogen and platelet function with thromboelastography using c7E3 fab
    Sharma, SK
    Philip, J
    Wiley, J
    ANESTHESIOLOGY, 1998, 89 (3A) : U879 - U879
  • [25] Immunolocalization of blocked and unblocked GP IIb-IIIa complexes in platelets during antithrombotic therapy with c7E3 Fab (ReoPro, abciximab)
    Nurden, A
    Poujol, C
    DurrieuJais, C
    Besse, P
    Jordan, R
    Wagner, C
    Nurden, P
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 184 - 184
  • [26] Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3 fab (Abciximab) linked to reduction in bleeding complications: Outcome in the EPILOG and EPIC trials
    Lincoff, AM
    Tcheng, JE
    Miller, DP
    Booth, JE
    Montague, EA
    Topol, EJ
    CIRCULATION, 1996, 94 (08) : 2185 - 2185
  • [27] Monoclonal antibody fragment against glycoprotein IIbIIIa, c7E3 Fab, prevents shear stress induced platelet shape change in vitro and in vivo
    Perlemuter, K
    Ajzenberg, N
    Masse, JM
    DuboisRande, JL
    Dupouy, P
    Baruch, D
    Castaigne, A
    Cramer, EM
    CIRCULATION, 1997, 96 (08) : 15 - 15
  • [28] Direct monitoring of c7E3 and fibrinogen binding to platelets allows differentiation of GP IIb/IIIa blockade and ticlopidine effects on platelet function.
    Bode, C
    Straub, A
    Kohler, B
    Moser, M
    Ruef, J
    Nordt, T
    Peter, K
    CIRCULATION, 1998, 98 (17) : 250 - 250
  • [29] Acute profound thrombocytopenia after c7E3 fab therapy - Response
    Berkowitz, SD
    Harrington, RA
    Rund, MM
    Tcheng, JE
    CIRCULATION, 1997, 96 (10) : 3810 - 3810
  • [30] Polymer-coated stent wires eluting c7E3 Fab inhibit platelet aggregation in vitro.
    Baron, JH
    Ezekowitz, M
    Azrin, M
    deBono, DP
    Gershlick, AH
    AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 : TCT30 - TCT30
12345